Associated Papers
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Thorvaldsdottir B et al.
Leukemia, 2025
40275070 (PubMed )
Supplement: 41375_2025_2615_MOESM2_ESM.xlsx › Supplemental_Table_S3
Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients.
Vivancos Sánchez C et al.
Cancers, 2025
Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.
Dennis MJ et al.
Frontiers in Immunology, 2024
38348036 (PubMed )
Supplement: Table_2.xlsx › Supplement_Table_2
Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
Renault AL et al.
Breast Cancer Research : Bcr, 2022
Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing.
Southey MC et al.
Npj Breast Cancer, 2021
34887416 (PubMed )
Supplement: 41523_2021_360_MOESM1_ESM.pdf
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia.
Jiménez I et al.
Biomarker Research, 2021
34016160 (PubMed )
Supplement: 40364_2021_290_MOESM1_ESM.zip › renamed_0d75d.xlsx › Supplementary_table_4
Myoclonus in ataxia-telangiectasia.
Termsarasab P et al.
Tremor and Other Hyperkinetic Movements (new York, N.y.), 2015
Select a paper to view details